The Artificial Cornea and Corneal Implant Market growth is attributed to the increasing number of corneal diseases and disorders, technological advancements in artificial corneal implants, and the growing number of initiatives taken by various governments and private organizations to spread awareness about corneal diseases. The market is also driven by the rising geriatric population, increasing prevalence of corneal diseases, and the rising use of contact lenses and intraocular lenses. However, the high cost of the procedure and the lack of skilled professionals are expected to restrain the growth of the market.

Currently, artificial cornea and corneal implant market is projected to reach USD 599 million by 2026 from USD 418 million in 2021, at a CAGR of 7.4% from 2021 to 2026. The increasing prevalence of eye disorders and government initiatives to control visual impairment are further boosting the market growth. However, the high cost of ophthalmology devices and surgical procedures is expected to restrain the growth of this market during the forecast period.

Request for assumptions & how numbers were triangulated.
https://www.marketsandmarkets.com/requestsampleNew.asp?id=182165973

Market Drivers
• Increase in Blindness and Visual Impairment
• Technological Advancements

Market Restraints
• High Cost
• Stringent Regulatory Requirements

Market Segmentation
• By Product Type
• By End User

Competitive Landscape
• Major Players and Their Market Share
• Strategies Adopted by Key Players

The prominent players operating in the Artificial Cornea and Corneal Implant Market are AJL Ophthalmic (Spain), CorneaGen Inc. (US), Addition Technology, Inc. (US), LinkoCare Life Sciences AB (Sweden), Presbia plc (Ireland), Mediphacos (Brazil), Aurolab (India), Cornea Biosciences (US), DIOPTEX GmbH (Austria), EyeYon Medical (Israel), Massachusetts Eye and Ear (US), Florida Lions Eye Bank (US), SightLife (US), Advancing Sight Network (US), San Diego Eye Bank (US) and L V Prasad Eye Institute (LVPEI, India).

AJL Ophthalmic (Spain)
AJL offers the artificial corneal implant through the Ophthalmology segment. The company has a strong product portfolio and a wide geographic presence in over 80 countries globally.
Massachusetts Eye and Ear (US)

Massachusetts Eye and Ear provides primary care and serves as a referral center for inpatient and outpatient surgical and medical care. It also offers several types of corneal services that provide better quality care.

Download an Illustrative Overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=182165973

Florida Lions Eye Bank (US)
The Florida Lions Eye Bank has provided tissue to more than 44,000 cornea transplant recipients.
L V Prasad Eye Institute (LVPEI, India)

LVPEI has served over 30.6 million people, over 50% of them entirely free of cost, irrespective of the complexity of care needed. The LVPEI Eye Care network is spread across the Indian states of Telangana, Odisha, Andhra Pradesh, and Karnataka, with nearly 228 centers providing primary to advanced eye care services.

Recent Developments
• In June 2020, AJL Ophthalmic (Spain) received CE Mark approval for ENDO-K PRO. Product approval will enable company to provide its portfolio to end users.
• In January 2020, Mediphacos (Brazil) launched Keraring Intrastromal Corneal Ring. Product launch will enable company to capture market share.
• In April 2018, CorneaGen (US) acquired AcuFocus (US). This acquisition aimed at expanding the company’s presence in the artificial cornea and corneal implants market.
• In December 2020, L V Prasad Eye Institute (India) inaugurated its 200th Vision Centre in Telangana, India.

Content Source:
https://www.marketsandmarkets.com/Market-Reports/artificial-cornea-corneal-implant-market-182165973.html
https://www.marketsandmarkets.com/PressReleases/artificial-cornea-corneal-implant.asp
https://www.prnewswire.com/news-releases/artificial-cornea-and-corneal-implant-market-worth-599-million-by-2026--exclusive-report-by-marketsandmarkets-301225688.html